<DOC>
	<DOCNO>NCT01529853</DOCNO>
	<brief_summary>Primary Objective : To assess adult patient Idiopathic Pulmonary Fibrosis ( IPF ) safety tolerability ascend dos SAR156597 administer subcutaneously ( SC ) weekly 6-week period . Secondary Objectives : To assess adult patient IPF : - The pharmacodynamic effect SAR156597 , measure pulmonary function test ( PFTs ) , pulse oximetry patient report outcome peripheral blood biomarkers . - The trough plasma concentration SAR156597 - The potential immunogenicity SAR156597 .</brief_summary>
	<brief_title>To Evaluate Effect Different Doses SAR156597 Given Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description>The study consist screen period 28 day , treatment period 6 week post-treatment follow-up period 12 week . Total study duration 22 week .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Inclusion criterion : Adult ( age &gt; 18 year ) male female patient , Documented diagnosis IPF accord current American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/American Latin Thoracic Association ( ATS/ERS/JRS/ALTA ) guideline Exclusion criterion : Forced vital capacity ( FVC ) &lt; 50 % predict value Carbon monoxide diffuse lung capacity ( DLCO ) ( correct hemoglobin ) &lt; 35 % predict value Oxygen saturation &lt; 90 % pulse oximetry breathe ambient air rest ( sit position 10 min ) Known diagnosis significant respiratory disorder IPF Active vasculopathy use vasoactive drug Known HIV chronic viral hepatitis Patients active tuberculosis latent tuberculosis infection Evidence clinically significant , severe unstable , acute chronically progressive medical ( IPF ) surgical disorder , condition may affect patient safety judgment investigator Clinically significant abnormal ECG screen Clinically significant laboratory test screen Current history substance and/or alcohol abuse Females lactate pregnant . Use register therapy target treat IPF within 4 week prior screen Use cytotoxic/immunosuppressive agent include limited azathioprine , cyclophosphamide , methotrexate cyclosporine within 4 week prior screen The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>